Biosimilar drugmakers should remember that the best cake – and the best biosimilar – is one that you don’t have to share with competitors.
(…) Now, a second biosimilars wave – mostly related to monoclonal antibodies – is hitting, and drug makers worldwide are racing to launch these molecules. But biosimilars are not an easy business to break into and there are significant challenges (…)
Read more in The Medecine Maker
